28 completed, 5 unknown, 4 terminated, 3 active not recruiting. 45 Phase 2, 7 Phase 1, 4 Phase 3.
Follow Eylea: new trials by email Literature Review of Eylea trials Research Report on Eylea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) Study Aflibercept Injection, Ahmed Tube Surgery - Glaucoma | Phase 2 | Not yet recruiting | University of Miami | 100 | 2026-12-01 | 2026-10-23 |
| Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma ZIV-Aflibercept, Cemiplimab - Metastatic Uveal Melanoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 32 | 2024-11-04 | 2025-12-04 |
| Study of EYP-1901 in Patients With Diabetic Macular Edema (DME) EYP-1901, Aflibercept 2Mg/0.05Ml Inj,Oph - Diabetic Macular Edema | Phase 2 | Completed | EyePoint Pharmaceuticals, Inc. | 27 | 2024-01-15 | 2025-03-04 |
| 4D-150 in Patients With Diabetic Macular Edema 4D-150 IVT, Aflibercept IVT - Diabetic Macular Edema, Diabetic Retinopathy | Phase 2 | Active not recruiting | 4D Molecular Therapeutics | 72 | 2023-08-09 | 2026-08-21 |
| Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration CLS-AX, Aflibercept - Neovascular Age-related Macular Degeneration | Phase 2 | Completed | Clearside Biomedical, Inc. | 60 | 2023-05-31 | 2025-07-25 |
| Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) EYP-1901, Aflibercept 2mg/0.05mL Inj,Oph - Wet Age-related Macular Degeneration | Phase 2 | Completed | EyePoint Pharmaceuticals, Inc. | 161 | 2022-06-30 | 2025-10-15 |
| Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy Standard of Care, Aflibercept - Diabetic Retinopathy, DR | Phase 2 | Active not recruiting | AbbVie | 103 | 2022-04-04 | 2026-11-06 |
| A Pharmacokinetic stuDy of intRavitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Diabetic Macular Edema Intravitreal Aflibercept - Diabetic Macular Edema | Phase 2 | Withdrawn | Stanford University | 2020-12-01 | 2022-04-28 | |
| The Sahlgrenska Anti-VEGF Study Bevacizumab Injection, Aflibercept Injection - Neovascular Age-related Macular Degeneration | Phase 2 | Active not recruiting | Vastra Gotaland Region | 402 | 2020-09-03 | 2025-11-21 |
| ADVM-022 Intravitreal Gene Therapy for DME 6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept - Diabetic Macular Edema, Diabetic Retinopathy | Phase 2 | Completed | Adverum Biotechnologies, Inc. | 36 | 2020-05-28 | 2025-07-10 |
| A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. KSI-301, Aflibercept, Sham Procedure - Wet Macular Degeneration | Phase 2 / Phase 3 | Terminated | Kodiak Sciences Inc | 559 | 2019-10-08 | 2024-07-18 |
| A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD Drug: GB-102, Aflibercept - Neovascular Age-Related Macular Degeneration | Phase 2 | Completed | Graybug Vision | 56 | 2019-09-26 | 2022-01-19 |
| Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema OZURDEX, Eylea - Diabetic Macular Edema | Phase 2 | Withdrawn | Pradeepa Yoganathan | 2019-09-01 | 2019-11-13 | |
| Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma Stereotactic Body Radiation Therapy, Ziv-Aflibercept - Uveal Melanoma | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 3 | 2019-08-09 | 2025-09-24 |
| ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) Zimura, Eylea - Idiopathic Polypoidal Choroidal Vasculopathy | Phase 2 | Withdrawn | Ophthotech Corporation | 2018-11-01 | 2024-02-21 | |
| Intense Treatment Regimen With Intravitreal Aflibercept Injection Aflibercept Injection - Neovascular Age-Related Macular Degeneration | Phase 1 / Phase 2 | Unknown | Vitreous -Retina- Macula Consultants of New York | 30 | 2018-09-11 | 2019-01-10 |
| A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema Aflibercept, OPT-302, Sham intravitreal injection - Diabetic Macular Edema | Phase 1 / Phase 2 | Completed | Opthea Limited | 153 | 2018-01-16 | 2025-04-22 |
| Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema IVT aflibercept, Sham SC, SC CLS-TA - Diabetic Macular Edema | Phase 2 | Completed | Clearside Biomedical, Inc. | 71 | 2017-07-11 | 2021-05-13 |
| Intravitreal Aflibercept Injection for Radiation Retinopathy Trial Aflibercept - Radiation Retinopathy | Phase 2 | Unknown | Amy C Schefler, MD | 40 | 2017-07-05 | 2020-12-08 |
| Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization Aflibercept - Corneal Neovascularization | Phase 1 / Phase 2 | Terminated | Rabin Medical Center | 6 | 2017-03-02 | 2019-09-16 |
Showing 20 of 45. Sign in to see all of them.
Diabetic Retinopathy (6) · Macular Degeneration (5) · Vitreous Hemorrhage (3) · Choroidal Neovascularization (2) · Diabetes Mellitus (2) · Eye Diseases (2) · Macular Edema (2) · Polypoidal Choroidal Vasculopathy (2) · Retinal Diseases (2) · Retinal Vein Occlusion (2) · Uveal Melanoma (2) · Angioid Streaks (1) · Blindness (1) · Central Serous Chorioretinopathy (1) · Choroidal Effusions (1)
Clearside Biomedical, Inc. (3) · Arshad Khanani (2) · EyePoint Pharmaceuticals, Inc. (2) · National Cancer Institute (NCI) (2) · Ophthotech Corporation (2) · 4D Molecular Therapeutics (1) · AbbVie (1) · Adverum Biotechnologies, Inc. (1) · Amy C Schefler, MD (1) · Asan Medical Center (1) · California Retina Consultants (1) · Charles C Wykoff, PhD, MD (1) · Dana-Farber Cancer Institute (1) · East Florida Eye Institute (1) · Graybug Vision (1)
United States (35) · Germany (2) · Israel (2) · Latvia (2) · Puerto Rico (2) · Australia (1) · Canada (1) · Czechia (1) · Poland (1) · Slovakia (1) · South Korea (1) · Spain (1) · Sweden (1) · United Kingdom (1)
Thomas Ciulla, MD (2) · Adam Rothman, MD (1) · Ahmad Tarhini (1) · Ahmad Tarhini, MD, PHD (1) · Allen Ho, MD (1) · Amy C Schefler, MD (1) · Andrew Antoszyk, MD (1) · Arshad Khanani, MD (1) · Arshad M Khanani, MD (1) · Charles C Wykoff, PhD, MD (1) · Daniel Halperin (1) · David Brown, MD (1) · Dennis M Marcus, MD (1) · Frank G. Holz, MD, DPhil (1)
PMID 19549103, PMID 19936307, PMID 20136420, PMID 25001321, PMID 25595177, PMID 26114826, PMID 27020759, PMID 27124775, PMID 30957581, PMID 31917731, PMID 32041720, PMID 32584384, PMID 32829304, PMID 33077475, PMID 33320223, PMID 33734306, PMID 33956075, PMID 36604756, PMID 37260074, PMID 37972038, PMID 39620832, PMID 40522203
2015 (1), 2018 (1), N01CM00038 (1), N01CM00039 (1), N01CM00070 (1), N01CM00071 (1), N01CM62209 (1), P30CA016672 (1), P30CA033572 (1), UM1CA186705 (1)